INOVIQ (ASX:IIQ) has formed a Medical and Scientific Advisory Board (MSAB) aimed at advancing its liquid biopsy diagnostic and targeted cancer therapeutic programs, according to a Monday filing with the Australian bourse.
The MSAB includes oncologists and clinical researchers with specializations in cancer immunotherapy, hematology, and liquid biopsy technologies, the filing added.